Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Series A Preferred Stock	Series A Preferred Stock Preferred Stock
Beginning balance, preferred stock, outstanding (in shares) at Dec. 31, 2022							0
Beginning balance at Dec. 31, 2022	$ 364,188	$ 43	$ 611,739	$ (679)	$ (246,915)		$ 0
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2022		42,832,231
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as consideration for SciSafe earnout (in shares)		116,973
Stock issued as consideration for SciSafe earnout	2,263		2,263
Fees incurred for registration filings	(132)		(132)
Stock-based compensation	33,245		33,245
Stock option exercises (in shares)		239,043
Stock option exercises	507		507
Stock issued – on vested RSAs (in shares)		1,267,837
Stock issued – on vested RSA units	0	$ 1	(1)
Settlement of Global Cooling escrow (in shares)		(216,024)
Settlement of Global Cooling escrow	(5,115)		(5,115)
Common stock shares issued (in shares)		927,165
Common stock shares issued	10,375	$ 1	10,374
Other comprehensive income	334			334
Net loss	(68,002)				(68,002)
Ending balance, preferred stock, outstanding (in shares) at Dec. 31, 2023							0
Ending balance at Dec. 31, 2023	337,663	$ 45	652,880	(345)	(314,917)		$ 0
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2023		45,167,225
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as consideration for SciSafe earnout	0
Stock-based compensation	30,923		30,923
Stock option exercises (in shares)		90,250
Stock option exercises	202		202
Stock issued – on vested RSAs (in shares)		1,649,290
Stock issued – on vested RSA units	(64)	$ 2	(66)
Other comprehensive income	369			369
Net loss	(20,184)				(20,184)
Ending balance, preferred stock, outstanding (in shares) at Dec. 31, 2024						0	0
Ending balance at Dec. 31, 2024	$ 348,909	$ 47	683,939	24	(335,101)		$ 0
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2024	46,906,765	46,906,765
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued as consideration for SciSafe earnout	$ 0
Stock-based compensation	22,993		22,993
Stock option exercises (in shares)		10,000
Stock option exercises	18		18
Stock issued – on vested RSAs (in shares)		1,068,803
Stock issued – on vested RSA units	$ 0	$ 1	(1)
Common stock shares issued for PanTHERA Transaction (in share)	213,360
Common stock shares issued for PanTHERA Transaction	$ 4,455
Other comprehensive income	108			108
Net loss	(4,595)				(4,595)
Ending balance, preferred stock, outstanding (in shares) at Dec. 31, 2025						0	0
Ending balance at Dec. 31, 2025	$ 371,888	$ 48	$ 711,404	$ 132	$ (339,696)		$ 0
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2025	48,198,928	48,198,928